Evaluating Ongoing Treatment After Platinum Chemotherapy

This segment focuses on a 72-year-old patient with metastatic urothelial (bladder) cancer who has completed six cycles of cisplatin plus gemcitabine with a good partial response but residual disease. The central question is whether to stop treatment and observe, or to move directly into maintenance immunotherapy.

The discussion highlights how common this scenario is in real-world practice: older patients with multiple comorbidities, partial response to platinum chemotherapy, and significant worry about stopping treatment. The speakers explain that, although imaging shows no progression, most responses to platinum are relatively short-lived, and some patients may experience rapid progression that can close the window for further therapy.

They emphasize shared decision-making, addressing patient anxiety, goals, and lifestyle. Maintenance immune checkpoint blockade is presented as a strategy to prolong disease control, reduce the risk of losing the chance for additional therapy, and potentially extend survival.